BMS-191011, an opener of large-conductance Ca2+-activated potassium channels, dilates rat retinal arterioles in vivo

Biological and Pharmaceutical Bulletin

Volumn 34, Issue 1, 2011, Pages 150-152

  Mori, Asami ^a   Suzuki, Sachi ^a   Sakamoto, Kenji ^a   Nakahara, Tsutomu ^a   Ishii, Kunio ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

BMS 191011; Large conductance Ca2+ activated K+ channel opener; NS 1619; Retinal blood vessel

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; 3 [(5 CHLORO 2 HYDROXYPHENYL)METHYL] 5 [4 (TRIFLUOROMETHYL)PHENYL] 1,3,4 OXADIAZOL 2(3H) ONE; BMS 191011; IBERIOTOXIN; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTERIOLE; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG MECHANISM; HEART RATE; IN VIVO STUDY; MALE; NONHUMAN; RAT; RETINA ARTERY;

ANIMALS; BENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MALE; OXADIAZOLES; RATS; RATS, WISTAR; RETINA; RETINAL ARTERY; VASODILATION; VASODILATOR AGENTS;

EID: 78951476867     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.34.150     Document Type: Article

References (24)

1. Schmetterer L., Wolzt M., Diabetologia, 42, 387-405 (1999).
2. Ghirlanda G., Di Leo M. A., Caputo S., Cercone S., Greco A. V., Diabetes Metab. Rev., 13, 15-35 (1997).
3. De la Cruz J. P., González-Correa J. A., Guerrero A., de la Cuesta F. S., Diabetes Metab. Res. Rev., 20, 91-113 (2004).
4. Flammer J., Orgül S., Costa V. P., Orzalesi N., Krieglstein G. K., Serra L. M., Renard J. P., Stefánsson E., Prog. Retin. Eye Res., 21, 359-393 (2002).
5. Grieshaber M. C., Flammer J., Curr. Opin. Ophthalmol., 16, 79-83 (2005).
6. Benedito S., Prieto D., Nielsen P. J., Nyborg N. C., Exp. Eye Res., 52, 575-579 (1991).
7. Haefliger I. O., Flammer J., Luscher T. F., Invest. Ophthalmol. Vis. Sci., 33, 2340-2343 (1992).
8. Delaey C., van de Voorde J., Ophthalmic. Res., 32, 249-256 (2000).
9. Okuno T., Oku H., Sugiyama T., Yang Y., Ikeda T., Invest. Ophthalmol. Vis. Sci., 43, 784-789 (2002).
10. Bolotina V. M., Najibi S., Palacino J. J., Pagano P. J., Cohen R. A., Nature (London), 368, 850-853 (1994).
11. Mistry D. K., Garland C. J., Br. J. Pharmacol., 124, 1131-1140 (1998).
12. Tanaka Y., Koike K., Toro L., J. Smooth Muscle Res., 40, 125-153 (2004).
13. Hayabuchi Y., Nakaya Y., Matsuoka S., Kuroda Y., Heart Vessels, 13, 9-17 (1998).
14. Otsuka K., Tanaka H., Horinouchi T., Koike K., Shigenobu K., Tanaka Y., J. Smooth Muscle Res., 38, 117-129 (2002).
15. Fleming I., Busse R., Hypertension, 47, 629-633 (2006).
16. Hewawasam P., Ding M., Chen N., King D., Knipe J., Pajor L., Ortiz A., Gribkoff V. K., Starrett J., Bioorg. Med. Chem. Lett., 13, 1695-1698 (2003).
17. Romine J. L., Martin S. W., Meanwell N. A., Gribkoff V. K., Boissard C. G., Dworetzky S. I., Natale J., Moon S., Ortiz A., Yeleswaram S., Pajor L., Gao Q., Starrett J. E. Jr., J. Med. Chem., 50, 528-542 (2007).
18. Edwards G., Niederste-Hollenberg A., Schneider J., Noack T., Weston A. H., Br. J. Pharmacol., 113, 1538-1547 (1994).
19. Kaneko Y., Saito M., Mori A., Sakamoto K., Nakahara T., Ishii K., J. Ocul. Pharmacol. Ther., 22, 317-322 (2006).
20. Mori A., Saito M., Sakamoto K., Narita M., Nakahara T., Ishii K., Eur. J. Pharmacol., 570, 135-141 (2007).
21. Berkowitz B. A., Lukaszew R. A., Mullins C. M., Penn J. S., Invest. Ophthalmol. Vis. Sci., 39, 391-396 (1998).
22. Ogawa N., Saito M., Mori A., Sakamoto K., Kametaka S., Nakahara T., Ishii K., Naunyn-Schmiedeberg's Arch. Pharmacol., 375, 323-328 (2007).
23. Quignard J. F., Harley E. A., Duhault J., Vanhoutte P. M., Félétou M., J. Cardiovasc. Pharmacol., 42, 379-388 (2003).
24. Cuppoletti J., Malinowska D. H., Tewari K. P., Chakrabarti J., Ueno R., Biochim. Biophys. Acta, 1768, 1083-1092 (2007).